Final Results of the Prospective ADVATE® Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII
Amy D Shapiro,1 Alejandro Fernandez,2 Jerome Teitel,3 Jaco Botha,2 Kate Khair4 1Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA; 2Takeda Pharmaceutical International AG, Zürich, Switzerland; 3St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 4Centre for Outcomes a...
Guardado en:
Autores principales: | Shapiro AD, Fernandez A, Teitel J, Botha J, Khair K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e8f7b0a0de8f401b952367e5ac65e494 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Microfluidic hemophilia models using blood from healthy donors
por: Xinren Yu, et al.
Publicado: (2020) -
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Haowei (Linda) Sun, et al.
Publicado: (2021) -
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Jennifer Stimec, et al.
Publicado: (2021) -
A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
por: David MARKS, et al.
Publicado: (2021) -
Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate-DVI) Concentrate and its Low-Dose Use
por: Dagmar M. Hajducek, et al.
Publicado: (2021)